Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Pacira Pharma (PCRX) Misses Q2 EPS by 8c
August 2, 2017 7:33 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of ($0.11), $0.08 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $70.9 million versus the consensus estimate of $73.6 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More


